NEW YORK (GenomeWeb) – GenomeDx Biosciences announced today that it has signed an exclusive deal with Medison Pharma to distribute its Decipher Prostate Cancer Classifier in Israel and the Palestinian Authority.
Specific terms of the arrangement were not disclosed.
Decipher is a genomic, RNA expression-based test that predicts cancer aggressiveness with an assay of 22 validated biomarkers associated with metastatic disease. Developed by GenomeDx in collaboration with the Mayo Clinic, the test was first launched in the US in 2013.
"The use of advanced tools that can identify the genetic materials found in tumor cells allows us a better assessment of prostate cancer," David Margel a urologist at Israel's Rabin Medical Center, said in a statement. "It also enables us to adjust the treatment program on an individual basis for each patient according to the results of their own findings. By using this advanced genetic testing, we can reduce the exposure to related therapies in patients after prostatectomy."